Skip Navigation
  Print Page

Han Lab: Unit on Metabolism and Neuroendocrinology

Skip sharing on social media links
Share this:
Skip Internal Navigation ​​​

Research Areas

The goal of our translational research is to gain insight into the neuroendocrine regulation of human energy homeostasis and cognitive function. We conduct clinical studies in healthy subjects as well as in patients with rare genetic disorders associated with childhood obesity and intellectual, psychiatric, and/or behavioral abnormalities. Our laboratory studies aim to elucidate mechanisms within the central nervous system that control both metabolism and neurodevelopment. We hope that a better understanding of the pathophysiology of energy imbalance and cognitive impairment will lead to therapies for improving body composition and neurocognition.

Genotype-phenotype correlation studies in WAGR/11p deletion syndrome

We have been conducting a comprehensive genotype-phenotype correlation study in patients with WAGR (Wilms tumor, aniridia, genitourinary anomalies, mental retardation) syndrome, which is caused by heterozygous contiguous gene deletions of variable size in the chromosome 11p13 region. We previously observed that haploinsufficiency for BDNF, the gene that encodes brain-derived neurotrophic factor (BDNF), is associated with higher prevalence of childhood obesity and higher scores on a hyperphagia questionnaire. BDNF is widely expressed throughout the nervous system and plays an important role in neuronal development and synaptic plasticity. In animal studies, BDNF appears to function downstream of the leptin signaling pathway to regulate appetite and energy balance. Our findings support the role of BDNF in human energy homeostasis. We have been conducting further studies to characterize the role of BDNF in neurocognitive function because Bdnf+/− mice are not only hyperphagic and obese but also display learning deficits, behavioral abnormalities, and decreased thermal pain response. In a cohort of 31 patients with WAGR syndrome, we observed that BDNF haploinsufficiency was associated with significantly lower scores on a parent-completed questionnaire assessing behavior responses to injuries or illnesses considered painful to most people. The findings suggest that BDNF plays a role in human nociception. Studies are currently under way to examine detection and pain thresholds for hot and cold stimuli. Tests of cognitive and adaptive function, psychiatric symptoms, and autism spectrum diagnoses are also ongoing. A treatment study using a BDNF agonist in patients with BDNF haploinsufficiency is being prepared.

BDNF in Prader-Willi syndrome

We have also been studying patients with Prader-Willi syndrome (PWS), which is caused by a lack of paternally expressed genes on chromosome 15q11-13. Patients with PWS typically present with hypotonia and poor feeding in the neonatal period followed by marked weight gain and severe hyperphagia between the ages of 1 and 5 years. PWS is also associated with cognitive impairment and behavioral abnormalities. We conducted a pilot study comparing 13 PWS children with 13 age-/sex-matched lean controls and 13 age/sex/body mass index (BMI)–matched obese controls. We observed that patients with PWS had significantly lower serum BDNF than did the lean or obese controls. Lower serum BDNF suggests insufficient central nervous system production of BDNF because BDNF in peripheral circulation is believed to reflect cerebral output of BDNF. Decreased BDNF may be a potential cause for the disordered satiety and morbid obesity associated with PWS. BDNF insufficiency may also contribute to the neurocognitive abnormalities observed in PWS. We aim to confirm these findings in a larger cohort of patients with PWS and to examine possible associations between cognitive function and serum BDNF concentrations.

BDNF in obesity and neurocognitive function

We are also investigating the role of BDNF in other conditions associated with childhood obesity (e.g., melanocortin 4-receptor mutations) and/or neurocognitive impairment (e.g., autism spectrum disorders, in collaboration with Susan Swedo's research group). We are also studying the role of single-nucleotide polymorphisms of the BDNF gene locus in body weight regulation and cognitive function in healthy adults and children. In collaboration with Joel Kleinman's research group, we are examining the associations of BDNF genotype with BMI and hypothalamic BDNF expression in cadaveric brain tissue from adults with sudden death.

Leptin in ciliopathy-associated obesity syndromes

In collaboration with Leslie Biesecker's research group, we have been studying patients with Bardet-Biedl syndrome (BBS), a cilopathy associated with obesity. Animal models of cilia dysfunction have demonstrated defects in leptin receptor trafficking and signaling. In our human studies, we have observed that patients with BBS (n=50) have nearly two-fold higher serum leptin concentrations (p<0.001) than age/sex/race/BMI–matched control subjects (n=100). Hyperleptinemia out of proportion to degree of adiposity suggests that leptin resistance may be the causative etiology of obesity in BBS. We are currently seeking to replicate this observation in patients with Alström syndrome, a disorder that is distinct from BBS but is also associated with cilia dysfunction.

Nutritional therapy in boys with constitutional growth delay

In collaboration with Nelly Mauras, we have been studying children with constitutional delay of growth and maturation (CDGM), a condition characterized by short stature, delayed skeletal maturation, and late entry into puberty. In general, children with CDGM tend to be thin, with a growth pattern reminiscent of nutritional insufficiency. Our earlier investigations demonstrated higher total energy expenditure in boys with CDGM than in size-matched younger boys or in age-matched taller boys, suggesting a state of hypermetabolism. These observations led us to examine whether supplemental nutrition can augment growth in children with CDGM. Twenty prepubertal boys with CDGM were randomized (n=10/group) to 6 months' observation or daily nutritional supplementation, followed by additional daily growth hormone therapy in all subjects for another 12 months. Height, weight, lean body mass, hormones, and nutrition markers increased comparably in both groups through 18 months, indicating no additional benefit from nutritional supplementation.

Last Updated Date: 11/30/2012
Last Reviewed Date: 11/30/2012

Contact Information

Name: Dr Joan Han
Assistant Clinical Investigator
Unit on Metabolism and Neuroendocrinology
Phone: 301-435-7820
Fax: 301-402-0574
Email: hanjo@mail.nih.gov

Staff Directory
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology